As cancer drug prices rise, it remains unclear whether the cost of new interventions is
related to their beneficial impact for patients at a societal-level. Using data for 2003–2015 …

Objectives We investigated how health technology assessment (HTA) organizations around
the world have handled drug genericization (an allowance for future generic drug entry and …

A systematic review (SR) can provide rigorous and complete evidence to support decision
makers who consider both the effectiveness and cost-effectiveness of health interventions. A …

Background There are indications of staggered market entry of medicines in the national
markets, with medicines being marketed first in countries with high prices. This study aimed …

Objective The cost-effectiveness of apixaban was compared with enoxaparin for prevention
of postoperative venothromboembolic events (VTE) in gynecologic oncology patients …

Introduction: Hepatocellular carcinoma (HCC) is the most common form of liver cancer
worldwide and carries a poor prognosis. Historically, sorafenib was the only available …

Importance Pharmacy benefit managers (PBMs) play a major role in the provision of
pharmacy services by acting as intermediaries between pharmacies, plan sponsors …

This study aimed to analyze four current pathways affecting the listing and post-listing prices
of new orphan drugs (ODs) in South Korea. These mechanisms were:(1) essential OD,(2) …

Background Understanding the economic value of deucravacitinib and apremilast could
assist treatment decision-making for patients with moderate to severe plaque psoriasis …

Importance Measuring drug price inflation is challenging because new drugs continually
enter the market, some drugs transition from branded to generic, and current inflation …